Yahoo Web Search

  1. Ad
    related to BRISTOL-MYERS SQUIBB COMPANY
  1. Roche RHHBY announced that the FDA has granted Breakthrough Therapy designation (BTD) to its lymphoma drug Gazyva (obinutuzumab) for a new indication. The agency granted BTD to the drug based ...

  2. 25 Dividend Stocks That Analysts Love the Most

    Kiplinger via Yahoo FinanceSep 11 19:54 PM

    Analysts forecast the bank to generate average annual earnings growth of 7.8% over the next three to five years, according to data from S&P Global Market Intelligence. Add in a yield of more ...

  3. 2 Large-Cap Companies Declare Dividends

    GuruFocus.com via Yahoo FinanceSep 12 17:36 PM

    Shares of Bristol-Myers Squibb Co. (NYSE:BMY) rose 0.18% to $49.33 in extended trading on Wednesday after the drugmaker announced the quarterly dividend. On Nov. 1, it will ...

  4. Edited Transcript of CTLT earnings conference call or presentation 27-Aug-19 12:15pm GMT

    Thomson Reuters StreetEvents via Yahoo FinanceSep 02 8:39 AM

    Third, in June, we announced our agreement to purchase Bristol-Myers Squibb oral solid, biologics and sterile product manufacturing and packaging facility in Anagni, Italy ...

  5. MOVES-Credit Suisse bolsters life sciences banking team -memo

    Reuters via Yahoo FinanceSep 05 22:10 PM

    Credit Suisse Group AG has brought on three new senior investment bankers as it continues to build out its healthcare investment banking division, according to an internal memo reviewed by Reuters ...

  6. September 12, 2019 – Zacks Market Edge is a podcast hosted weekly by cks Stock Strategist Tracey Ryniec. Every week, host and Zacks stock strategist, Tracey Ryniec, will be joined by guests ...

  7. Roche (RHHBY) Reports Positive Data on Tecentriq & MS Drug

    Zacks via Yahoo FinanceSep 12 13:09 PM

    Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its MS drug in a phase III study.

  8. Renal Cell Carcinoma Space in Focus: Some Key Developments

    Zacks via Yahoo FinanceSep 13 13:36 PM

    In April 2019, the FDA had approved this combination for the same indication. Given its market potential, most pharma/biotech bigwigs are scurrying to grab a larger chunk of this pie. Evidently, the focus is on better and effective treatments.

  9. Pharmaceutical giant Sumitomo Dainippon Pharma has agreed to acquire a 10% stake in Swiss drugmaker Roivant Sciences for $3 billion. The deal will see the Japanese business take over Roivant's ...

  10. Roche RHHBY announced positive data on the immuno-oncology drug, Tecentriq (atezolizumab), from a late-stage study in patients with advanced non-small cell lung cancer (NSCLC). The phase III ...

  1. Ads
    related to BRISTOL-MYERS SQUIBB COMPANY